192 related articles for article (PubMed ID: 22937108)
21. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss.
Ryu M; Kulkarni OP; Radomska E; Miosge N; Gross O; Anders HJ
Kidney Int; 2011 Jan; 79(2):189-98. PubMed ID: 20962742
[TBL] [Abstract][Full Text] [Related]
22. The effect of progressive glomerular disease on megalin-mediated endocytosis in the kidney.
Vinge L; Lees GE; Nielsen R; Kashtan CE; Bahr A; Christensen EI
Nephrol Dial Transplant; 2010 Aug; 25(8):2458-67. PubMed ID: 20200006
[TBL] [Abstract][Full Text] [Related]
23. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
[TBL] [Abstract][Full Text] [Related]
24. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease.
Dufek B; Meehan DT; Delimont D; Cheung L; Gratton MA; Phillips G; Song W; Liu S; Cosgrove D
Kidney Int; 2016 Aug; 90(2):300-310. PubMed ID: 27165837
[TBL] [Abstract][Full Text] [Related]
25. Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease.
Massella L; Onetti Muda A; Faraggiana T; Bette C; Renieri A; Rizzoni G
Kidney Int; 2003 Nov; 64(5):1787-91. PubMed ID: 14531812
[TBL] [Abstract][Full Text] [Related]
26. Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome.
Guo J; Song W; Boulanger J; Xu EY; Wang F; Zhang Y; He Q; Wang S; Yang L; Pryce C; Phillips L; MacKenna D; Leberer E; Ibraghimov-Beskrovnaya O; Ding J; Liu S
Hum Gene Ther; 2019 Jul; 30(7):865-881. PubMed ID: 30808234
[TBL] [Abstract][Full Text] [Related]
27. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease.
Gross O; Girgert R; Beirowski B; Kretzler M; Kang HG; Kruegel J; Miosge N; Busse AC; Segerer S; Vogel WF; Müller GA; Weber M
Matrix Biol; 2010 Jun; 29(5):346-56. PubMed ID: 20307660
[TBL] [Abstract][Full Text] [Related]
28. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M
Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109
[TBL] [Abstract][Full Text] [Related]
29. Glomerular pathology in Alport syndrome: a molecular perspective.
Cosgrove D
Pediatr Nephrol; 2012 Jun; 27(6):885-90. PubMed ID: 21455721
[TBL] [Abstract][Full Text] [Related]
30. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects.
Abrahamson DR; Isom K; Roach E; Stroganova L; Zelenchuk A; Miner JH; St John PL
J Am Soc Nephrol; 2007 Sep; 18(9):2465-72. PubMed ID: 17699809
[TBL] [Abstract][Full Text] [Related]
31. Hyperthermia with mild electrical stimulation protects pancreatic β-cells from cell stresses and apoptosis.
Kondo T; Sasaki K; Matsuyama R; Morino-Koga S; Adachi H; Suico MA; Kawashima J; Motoshima H; Furukawa N; Kai H; Araki E
Diabetes; 2012 Apr; 61(4):838-47. PubMed ID: 22362176
[TBL] [Abstract][Full Text] [Related]
32. Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome.
Nakanishi K; Iijima K; Kuroda N; Inoue Y; Sado Y; Nakamura H; Yoshikawa N
J Am Soc Nephrol; 1998 Aug; 9(8):1433-40. PubMed ID: 9697665
[TBL] [Abstract][Full Text] [Related]
33. An update on the pathomechanisms and future therapies of Alport syndrome.
Noone D; Licht C
Pediatr Nephrol; 2013 Jul; 28(7):1025-36. PubMed ID: 22903660
[TBL] [Abstract][Full Text] [Related]
34. RNA-seq analysis of gene expression profiles in isolated stria vascularis from wild-type and Alport mice reveals key pathways underling Alport strial pathogenesis.
Dufek B; Meehan DT; Delimont D; Wilhelm K; Samuelson G; Coenen R; Madison J; Doyle E; Smyth B; Phillips G; Gratton MA; Cosgrove D
PLoS One; 2020; 15(8):e0237907. PubMed ID: 32822386
[TBL] [Abstract][Full Text] [Related]
35. Bull terrier hereditary nephritis: a model for autosomal dominant Alport syndrome.
Hood JC; Savige J; Hendtlass A; Kleppel MM; Huxtable CR; Robinson WF
Kidney Int; 1995 Mar; 47(3):758-65. PubMed ID: 7752574
[TBL] [Abstract][Full Text] [Related]
36. Histopathology, ultrastructure, and clinical phenotypes in thin glomerular basement membrane disease variants.
Liapis H; Gökden N; Hmiel P; Miner JH
Hum Pathol; 2002 Aug; 33(8):836-45. PubMed ID: 12203217
[TBL] [Abstract][Full Text] [Related]
37. Albumin contributes to kidney disease progression in Alport syndrome.
Jarad G; Knutsen RH; Mecham RP; Miner JH
Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675
[TBL] [Abstract][Full Text] [Related]
38. Two Specific Sulfatide Species Are Dysregulated during Renal Development in a Mouse Model of Alport Syndrome.
Gessel MM; Spraggins JM; Voziyan PA; Abrahamson DR; Caprioli RM; Hudson BG
Lipids; 2019 Jun; 54(6-7):411-418. PubMed ID: 31197846
[TBL] [Abstract][Full Text] [Related]
39. Laminin-1 reexpression in Alport mouse glomerular basement membranes.
Abrahamson DR; Prettyman AC; Robert B; St John PL
Kidney Int; 2003 Mar; 63(3):826-34. PubMed ID: 12631063
[TBL] [Abstract][Full Text] [Related]
40. Alport syndrome--insights from basic and clinical research.
Kruegel J; Rubel D; Gross O
Nat Rev Nephrol; 2013 Mar; 9(3):170-8. PubMed ID: 23165304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
